Year: 2026

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced translational data from the GOBLET and AWARE-1 trials will be presented at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting at McCormick Place, Chicago, Illinois, from May 29-June 2, 2026. Pelareorep is an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. “These...

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) — All In FutureTech Alliance Inc. (Nasdaq: AGAE) (“AIFA” or the “Company”) today announced that the Company has entered into a package of transaction definitive agreements to acquire an aggregate 57.67% controlling interest in HyalRoute Fiber-Optic Communication Group (“HyalRoute”). This acquisition marks a major milestone in AIFA’s transformation into a global technology operating platform with “optics-centered” AI infrastructure. 1. US$10.00 Per Share Reference Price: AIFA Board and Management’s Strategic Reassessment of the Company’s Value and Market Recognition Based on an overall valuation of US$4.0 billion for HyalRoute, the total consideration for the acquisition of a 57.67% controlling interest is US$2.3068 billion, payable entirely through the issuance of newly issued AGAE common...

BEIJING, May 22, 2026 (GLOBE NEWSWIRE) — Global Mofy AI Limited (the “Company” or “Global Mofy”) (Nasdaq: GMM), a generative AI-driven technology solutions provider engaged in virtual content production and the development of 3D digital assets, today announced the pricing of its registered direct offering (the “Offering”) of (i) 8,247,420 Class A ordinary shares, par value US$0.00003 each of the Company (“Class A Ordinary Shares”), (ii) 8,247,420 series A warrants to purchase up to 8,247,420 Class A Ordinary Shares (“Series A Warrants”), (iii) 8,247,420 series B warrants to purchase up to 8,247,420 Class A Ordinary Shares (“Series B Warrant”, together with the Series A Warrant, the “Warrants”) at an offering price of $0.97 per Class A Ordinary Share and accompanying Warrants (the “ Offering Price”) for total gross proceeds of approximately...

EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (NASDAQ: BIOA) (“BioAge”, “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • Jefferies Global Healthcare Conference (New York, June 3–4, 2026): Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief Strategy Officer, are scheduled to participate in a fireside chat on Thursday, June 4 at 3:45–4:15 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. • Goldman Sachs Global Healthcare Conference (Miami Beach, June 8–10, 2025): Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief...

JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) — Moomoo, a leading global investment and trading platform that empowers self-directed investors with advanced market data and professional-grade tools, today announced the expansion of its cryptocurrency trading services to investors in Texas alongside the launch of its new Direct Crypto Deposit & Withdraw feature for U.S. users. Together, these milestones mark a significant step forward in moomoo’s strategy to deliver a seamless, multi-asset investing experience that bridges the gap between traditional finance and Web3. Texas-based investors can trade 52 cryptocurrencies on moomoo with $0 commission* and an industry-competitive transaction fee as low as 0.49%*. With this expansion, moomoo crypto is now available in California, New Jersey, Pennsylvania, Texas, and additional...

BOSTON, MA, May 22, 2026 (GLOBE NEWSWIRE) — Netcapital Inc. (Nasdaq: NCPL) (“Netcapital” or the “Company”), a capital markets technology company leveraging regulatory infrastructure and proprietary market data to deliver AI-powered solutions, has scheduled a business update conference call for Thursday, May 28, 2026, at 4:30 p.m. ET. Newly appointed Chief Executive Officer Todd Violette will lead the discussion and provide investors with an overview of Netcapital’s strategic direction, including the Company’s ongoing business transformation, near-term priorities, and plans to leverage its regulatory infrastructure, proprietary market data, and AI-powered solutions to support growth-stage companies and expand its private capital markets platform. Conference Call Information The Company will host an investor...

VANCOUVER, British Columbia, May 22, 2026 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announced today that it has entered into a Technology Evaluation and License Option Agreement (the “Agreement”) with one of the world’s largest multinational food companies (the “Partner”). Under the terms of the Agreement, the Partner will conduct a commercial-scale evaluation of EnWave’s proprietary Radiant Energy Vacuum (“REV™”) dehydration technology for potential application across multiple food categories within the Partner’s extensive global product portfolio. Subject to successful completion of the evaluation program, the Agreement provides the Partner with the option to negotiate one or more commercial royalty-bearing licenses for the use of REV™ technology. The Partner...

In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and suppress key inflammatory pathways associated with chronic psoriatic disease HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials,  today announced preclinical data from its CYPS317 program for psoriasis presented at the Society for Investigative Dermatology 2026 Annual Meeting, held May 13-15, 2026, in Chicago, Illinois. A link to the poster can be found here. Psoriasis is a chronic inflammatory skin disease driven by dysregulated innate and adaptive immunity, with the IL-23/Th17...